RxDoctor Payments Data

Susan Brian, MD

Endocrinology, Diabetes & Metabolism · Topeka, KSNPI 1710928882

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,961 of the $9,320 with a category attached, or 74.7%. Eli Lilly accounts for 83.5% of it on its own, with 7 other manufacturers making up the rest.

$9,320in general payments, 2019–2025

Across 111 payments — averaging $83.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$8K
  • Amgen$1K
  • Ascensia Diabetes Care US Inc.$58
  • Dexcom, Inc.$49
  • Pfizer$41
  • Insulet Corporation$34
  • plus $33 from 2 others
$2,819,602in research payments, 2019–2025

Across 427 payments — averaging $6603.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2.6M
  • Amgen$107K
  • Bayer$68K
  • Novo Nordisk AS$67K
  • Dexcom, Inc.$12K
  • Eli Lilly Export S.A. Puerto Rico Branch$2K

What the payments were for

  • Travel & lodging$6,96175%
  • Food & beverage$2,35925%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,320 in reported general payments places this provider in the 80th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.

See all endocrinology, diabetes & metabolism providers in Kansas

Medicare billing

Part B allowed, 2024
$75,094
Medicare patients
558
Services billed
1,198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide130$162,171
SomavertPegvisomant11$135,529
OzempicSemaglutide81$106,192
JardianceEmpagliflozin79$70,807
SynthroidLevothyroxine Sodium239$17,131
TradjentaLinagliptin17$8,509
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$4,876
Levothyroxine Sodium485$4,107
Testosterone24$2,590
Nano 2nd Gen Pen NeedlePen Needle, Diabetic20$2,086
Potassium Citrate ErPotassium Citrate14$1,679
Ultra-Fine Short Pen NeedlePen Needle, Diabetic19$1,572
Cinacalcet Hcl40$1,563
Novolog FlexpenInsulin Aspart11$1,454
Estradiol11$1,282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerSomavert, Levoxyl$41$135,72125 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.

Other endocrinology, diabetes & metabolism in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →